GOVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
GeoVax Labs Inc (GOVX) is not a good buy for a beginner investor with a long-term strategy at this time. The stock exhibits bearish technical indicators, weak financial performance, and lacks significant positive catalysts or trading signals. The company's recent financials show a complete drop in revenue and negative earnings, which are concerning for long-term investment. Additionally, there is no recent news or significant trading activity to suggest a strong upward momentum. Given the lack of strong buy signals and the investor's preference for long-term stability, it is advisable to hold off on investing in this stock.
The technical indicators for GOVX are bearish. The MACD is above 0 but positively contracting, suggesting weakening momentum. The RSI is neutral at 23.241, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading below key pivot levels, with resistance at 2.862 and support at 2.373. Overall, the technical setup does not indicate a strong buy opportunity.
The company received formal Scientific Advice from the EMA, three peer-reviewed publications highlighted clinical and preclinical data, and two U.S. patents were either allowed or issued. These developments could be positive in the long term if they translate into financial growth.
The stock has experienced a significant regular market decline of -9.41%, and its financials for Q3 2025 show a complete revenue drop (-100% YoY) and negative earnings (EPS dropped to -7.79, down -65.68% YoY). There is no recent news or significant trading activity to suggest a reversal in sentiment.
In Q3 2025, GeoVax Labs reported a complete revenue drop (-100% YoY), an increase in net income loss to -6,318,914 (up 8.66% YoY), and a significant decline in EPS to -7.79 (-65.68% YoY). Gross margin remained stable at 100%. The financial performance indicates poor growth trends and weak fundamentals.
Roth Capital analyst Jonathan Aschoff has a Buy rating on the stock with a $14 price target, citing positive developments like EMA Scientific Advice, peer-reviewed publications, and new patents. However, these ratings are based on potential long-term catalysts rather than immediate financial performance or market sentiment.
